OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4883
Abstract: Background IL-17F shares structural homology and pro-inflammatory function with IL–17A. Preclinical and early clinical data support neutralisation of IL-17F, in addition to IL–17A, as a novel targeting approach in psoriatic disease. Objectives The objective of… read more here.
Keywords: response; bkz; ucb pharma; active psa ... See more keywords
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Pharmacology and Therapeutics"
DOI: 10.5414/cp203516
Abstract: Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This analysis characterized the pharmacokinetics (PK) of tofacitinib in adult patients with active PsA and evaluated the impact of covariates… read more here.
Keywords: population pharmacokinetics; patients active; pharmacokinetics tofacitinib; active psa ... See more keywords